Cincinnati Children's research helps pave way for newly approved use of drug

(Cincinnati Children's Hospital Medical Center) Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the US Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.